3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Classical hematology
1
Conditions
Neoplasms
14
Venous Thromboembolism
11
Venous Thrombosis
4
Thrombosis
3
Pulmonary Embolism
3
Multiple Myeloma
3
Upper Extremity Deep Vein Thrombosis
2
Lung Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Thromboembolism
1
Stomach Neoplasms
1
Recurrence
1
Prostatic Neoplasms
1
Prevention of Venous Thromboembolism
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia
1
Inflammation
1
Immune System Diseases
1
Hemorrhage
1
Hematologic Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Interventions
padeliporfin
5
Nivolumab
3
vedolizumab
2
atezolizumab
2
anlotinib
2
Therapeutics
2
Surveys and Questionnaires
2
Riluzole
2
Radiotherapy
2
LDP-02
2
Ipilimumab
2
Infliximab
2
Immunoglobulin G
2
Genetic Testing
2
Fecal Microbiota Transplantation
2
Disulfides
2
Carboplatin
2
CT-P13
2
tislelizumab
1
relatlimab
1
prednylidene
1
pembrolizumab
1
palladium-bacteriopheophorbide
1
olaparib
1
niraparib
1
ixabepilone
1
ferumoxtran-10
1
enfortumab vedotin
1
deltacortene
1
darolutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Urogenital Neoplasms
×
Rivaroxaban
×
Clear all
NCT05920343
2025-07-10
PREVENT-GU
Ottawa Hospital Research Institute
Phase 2/3
Recruiting
120 enrolled